The European Parliament’s Intergroup on Cancer and Rare Diseases official report of its high-level hearing on the revision of the EU Pharmaceutical Legislation is out. The document summarizes the high-level discussion convened at the Intergroup Hearing held on July 10 in the European Parliament, Strasbourg.

The European Parliament’s Intergroup on Cancer and Rare Diseases convened a high-level hearing today in Strasbourg to discuss critical developments in the revision of the EU pharmaceutical legislation (often referred to as the ‘Pharma Package’). The session brought together Members of the European Parliament (MEPs), patient advocates, researchers, and industry leaders to debate the future of incentives, unmet medical needs, and governance at the European Medicines Agency (EMA).

On March 4, the co-chairs of the European Parliament Intergroup (IG) on Cancer & Rare Diseases hosted the official launch of its 2025 Annual Workplan. This event marks a pivotal moment in shaping Europe’s discourse on health policy, as legislators, policymakers, and key stakeholders gathered to discuss the priorities of the IG identified for this year and beyond. The IG, led by key voices in health policy across the European Parliament groups, is a sign of the continued focus on cancer and rare diseases on the EU agenda.   

The European Cancer Organisation (ECO), EURORDIS-Rare Diseases Europe, and the European Society for Paediatric Oncology (SIOPE) welcome a major initiative from the European Parliament's Conference of Presidents: the creation of a new ‘Intergroup on Cancer & Rare Diseases’ for the 2024-2029 legislature.